Evidence map›Paper›PMID 40365658›Full record

ArticleChemMedChem2025

Synthesis, Antimycobacterial Activity, and Computational Insight of Novel 1,4-Benzoxazin-2-one Derivatives as Promising Candidates against Multidrug-Resistant Mycobacterium Tuberculosis.

Maria Grazia Mamolo, Emanuele Carosati, Diletta Pasin, Alessandro De Logu, Gianluigi Cabiddu, Marko Jukič, Daniele Zampieri

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maria Grazia MamoloDepartment of Chemistry and Pharmaceutical Sciences, University of Trieste, Via L. Giorgieri 1, 34127, Trieste, Italy.
Emanuele CarosatiDepartment of Chemistry and Pharmaceutical Sciences, University of Trieste, Via L. Giorgieri 1, 34127, Trieste, Italy.
Diletta PasinS.O.C. Experimental and Clinical Pharmacology, IRCSS, RO Aviano, Via F. Gallini 2, 33081, Aviano, Italy.
Alessandro De LoguDepartment of Life and Environmental Sciences, University of Cagliari, Cittadella Universitaria di Monserrato, Monserrato, 09042, Cagliari, Italy.
Gianluigi CabidduDepartment of Life and Environmental Sciences, University of Cagliari, Cittadella Universitaria di Monserrato, Monserrato, 09042, Cagliari, Italy.
Marko JukičFaculty of Chemistry and Chemical Engineering, University of Maribor, Smetanova ulica 17, SI-2000, Maribor, Slovenia.
Daniele ZampieriDepartment of Chemistry and Pharmaceutical Sciences, University of Trieste, Via L. Giorgieri 1, 34127, Trieste, Italy.ORCID https://orcid.org/0000-0002-1397-7334

Funding

Slovenian Research and Innovation Agency J7-50043
6 · The paper itself

Abstract

In the search for new antitubercular agents, a series of 1,4-benzoxazinone-based compounds is designed, synthesized, and evaluated. These molecules show potent antimycobacterial activity, with a minimum inhibitory concentration between 2 and 8 μg mL

Indexed as

Antitubercular AgentsBenzoxazinesMycobacterium tuberculosisAnimalsChlorocebus aethiopsDose-Response Relationship, DrugDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureStructure-Activity RelationshipTuberculosis, Multidrug-ResistantVero CellsAntitubercular AgentsBenzoxazinesantimycobacterialbenzoxazinonescytotoxicitiesdockingsmenaquinone‐Bminimum inhibitory concentrations

Identifiers

PMID40365658
PMCPMC12276033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.